Obesity and Diabetes
Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
Published in Obesity and Diabetes Week, July 20th, 2009
Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) announced positive results from a 28-week dose-ranging study of pramlintide/metreleptin, a combination treatment comprising pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin, in overweight and obese patients. This Phase 2 study successfully characterized patients who responded best to treatment and also provided important information to inform dose selection.
At 28 weeks, evaluable patients with a starting body mass index (BMI) less than 35 kg/m2 (n=3D149), and treated with the highest pramlintide/metreleptin doses, experienced significantly more weight loss on...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Monash University
Link between obesity and diabetes discovered - World Journal of Gastroenterology
Pluronic L-81 is a potential anti-diabetic drug? - Arrin Background, Inc.
Arrin Background, Inc. Completes Reverse Merger and Announces Name Change to XerTech Inc. - Atherosclerosis
New atherosclerosis research from University of Poitiers discussed - Cardiology
Studies in the area of cardiology reported from Brigham and Women's Hospital - Diabetes
Scientists at University of Michigan target diabetes - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
